ResearcherCentre National de la Recherche ScientifiqueNo recent work listed
Romain Vasseur
Matched on ORCID iD 0000-0003-4179-9800; OpenAlex author ID A5017448776. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper
Papers 6
- The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. Co-author DOI 10.3390/cancers13225746↗
- Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Co-author DOI 10.1002/mc.23090↗
- TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Phosphorylation on S727. Co-author DOI 10.3390/cancers10080254↗
- The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting. First author DOI 10.1016/j.critrevonc.2017.01.002↗
- The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling … Co-author DOI 10.1016/j.bbagrm.2015.10.014↗
- The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-re… First author DOI 10.18632/oncotarget.3414↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Isabelle VAN SEUNINGEN · 6 shared papers, 2015–2021 · strength 0.49
- Paper The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological proc… DOI 10.1016/j.critrevonc.2017.01.002↗
- Paper The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. DOI 10.3390/cancers13225746↗
- Paper Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells o… DOI 10.1002/mc.23090↗
- Nicolas Jonckheere · 5 shared papers, 2015–2021 · strength 0.41
- Paper The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological proc… DOI 10.1016/j.critrevonc.2017.01.002↗
- Paper The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. DOI 10.3390/cancers13225746↗
- Paper TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Ph… DOI 10.3390/cancers10080254↗
- Nicolas Skrypek · 4 shared papers, 2015–2021 · strength 0.30
- Paper The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis. DOI 10.3390/cancers13225746↗
- Paper TGF-βRII Knock-down in Pancreatic Cancer Cells Promotes Tumor Growth and Gemcitabine Resistance. Importance of STAT3 Ph… DOI 10.3390/cancers10080254↗
- Paper The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cell… DOI 10.18632/oncotarget.3414↗
- Audrey Vincent · 3 shared papers, 2015–2019 · strength 0.19
- Paper Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells o… DOI 10.1002/mc.23090↗
- Paper The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cell… DOI 10.18632/oncotarget.3414↗
- Paper The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication… DOI 10.1016/j.bbagrm.2015.10.014↗
- Fatima Lahdaoui · 2 shared papers, 2019–2021 · strength 0.19
- Nicolas Stoup · 1 shared paper, 2021 · strength 0.11
- Mehdi El Amrani · 1 shared paper, 2019 · strength 0.08
- Stéphanie Truant · 1 shared paper, 2019 · strength 0.08
- Vincent Drubay · 1 shared paper, 2018 · strength 0.08
- Nihad Boukrout · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.